Skip to content
Stop using now Drug recall · FDA · Published April 30, 2013

Hospira Dobutamine Recall: Sterility Risk in IV Bags

Hospira recalls 44,748 bags of Dobutamine in 5% Dextrose due to confirmed leaking and lack of sterility assurance. Check your lot number.

🇺🇸 FDA recall #D-502-2013DrugHospira ›
Take action

Contact the company

Recalling firmHospira Inc.275 N Field Dr · Lake Forest, IL 60045-2579
✎ GovInfoNow plain-language explainer

Hospira Inc. is recalling Dobutamine in 5% Dextrose Injection, USP, specifically the 250 mg Total, 1000 mcg/mL 250 mL bags. The recall was issued because there is a confirmed report of leaking in the primary container, which leads to a lack of assurance that the product remains sterile. This affects approximately 44,748 bags distributed nationwide and in Puerto Rico. Read more at govinfonow.com/recall/47971-hospira-inc-recalls-dobutamine-in-5-dextrose-injection-usp-250.

Source Summary by GovInfoNow · govinfonow.com/recall/47971-hospira-inc-recalls-dobutamine-in-5-dextrose-injection-usp-250 · Updated October 13, 2026 · FDA enforcement record: FDA #D-502-2013

Cite this page

“Hospira Dobutamine Recall: Sterility Risk in IV Bags.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/47971-hospira-inc-recalls-dobutamine-in-5-dextrose-injection-usp-250. Based on FDA recall #D-502-2013 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-502-2013%22&limit=1).

The FDA announced on April 30, 2013, that Hospira Inc. voluntarily recalled Dobutamine Injection Bags due to a lack of assurance of sterility caused by leaking primary containers. The agency issued recall number D-502-2013 for the affected product.

How to tell if you have it

  • Brand: Hospira
  • Product: DOBUTamine in 5% Dextrose Injection, USP, 250 mg Total, 1000 mcg/mL 250 mL bag
  • NDC: 0409-2346-32
  • Lot: 11-309-KL

The hazard

The recall addresses a confirmed report of leaking in the primary container, which results in a lack of assurance of sterility for the Dobutamine Injection Bags.

Context

GovInfoNow's records show Hospira Inc. has 108 other recalls on record since April 5, 2012. Other recent recalls include a 2017-04-21 recall for hair particulates in syringes and a 2016-11-01 recall for broken ampule tips risking infection. Similar product recalls include Reliance's June 24, 2026 sterility risk recall, Fresenius Kabi's March 11, 2026 lack of sterility assurance recall, and Teva's March 17, 2026 sterility risk recall.

How to tell if you have this one

Look for Dobutamine in 5% Dextrose Injection, USP, 250 mg Total, 1000 mcg/mL 250 mL bag. The product is Rx only and manufactured by HOPIRA, INC., LAKE FOREST, IL 60045. Check for NDC 0409-2346-32 and Lot number 11-309-KL.

  • Brand
    Hospira
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Identify the Product

    Check if you have Dobutamine in 5% Dextrose Injection, USP with NDC 0409-2346-32 and Lot 11-309-KL.

  2. Stop Use Immediately

    Do not use the affected bags due to the confirmed risk of leaking and lack of sterility assurance.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 17 months after the firm started it.

1. Firm started the recall: Apr 30, 201312. FDA classified it Class II: Jun 3, 201323. Published in FDA’s Enforcement Report: Jun 12, 201334. FDA terminated the recall: Oct 8, 2014420132014
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-502-2013 (April 30, 2013) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-502-2013 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA